Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marina Pulido
Observed name:
Pulido, Marina
Institution:
Institut Bergonié
Observed institutions:
Inserm,
Centre de Recherche des Cordeliers,
Centre François Baclesse,
Institut Claudius Regaud,
Institut Bergonié,
Institut National du Cancer,
Centre Antoine Lacassagne,
Centre d'Investigation Clinique Plurithématique de Bordeaux
show all 8
ORCID:
0009-0004-3851-6157
Observed ORCID:
0009-0004-3851-6157
OpenAlex ID:
A5114045959
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial
2017
·
Maud Toulmonde
, Nicolas Penel
, et al.
·
JAMA Oncology
·
430
PDF
Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
2019
·
Maud Toulmonde
, Marina Pulido
, et al.
·
The Lancet Oncology
·
210
PDF
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials
2012
·
Carine A. Bellera
, Marina Pulido
, et al.
·
European Journal of Cancer
·
75
Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study
2013
·
Françoise Bonichon
, Jean Palussière
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
42
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
2018
·
Marina Pulido
, Guilhem Roubaud
, et al.
·
BMC Cancer
·
30
PDF
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial
2025
·
Hervé Bonnefoi
, Florence Lerebours
, et al.
·
The Lancet Oncology
·
29
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
2015
·
Nathalie Quenel-Tueux
, Marc Debled
, et al.
·
British Journal of Cancer
·
29
PDF
PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: Baseline characteristics and safety evaluation.
2021
·
Philippe Caillet
, Marina Pulido
, et al.
·
Journal of Clinical Oncology
·
27
Enhancing Abiraterone Acetate Efficacy in Androgen Receptor–positive Triple-negative Breast Cancer: Chk1 as a Potential Target
2018
·
Thomas Grellety
, Celine Callens
, et al.
·
Clinical Cancer Research
·
27
Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
2022
·
Mariella Spalato-Ceruso
, Fanny Bouteiller
, et al.
·
Journal of Hematology & Oncology
·
26
PDF
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
2020
·
Florence Lerebours
, Marina Pulido
, et al.
·
British Journal of Cancer
·
23
PDF
How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software
2016
·
Audrey Emmanuelle Dugué
, Marina Pulido
, et al.
·
Clinical Cancer Research
·
23
Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer
2011
·
Juliette Mathiaux
, Valérie Le Morvan
, et al.
·
Molecular Diagnosis & Therapy
·
23
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.
2023
·
Elisabeth Carola
, Marina Pulido
, et al.
·
Journal of Clinical Oncology
·
22
FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
2014
·
Yves Bécouarn
, Laurent Cany
, et al.
·
BMC Research Notes
·
16
PDF
Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide study
2024
·
Elena Paillaud
, Angéline Galvin
, et al.
·
Patient Education and Counseling
·
13
BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocol
2021
·
Stamatios Petousis
, Sabrina Croce
, et al.
·
International Journal of Gynecological Cancer
·
13
Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial.
2017
·
Maud Toulmonde
, Nicolas Penel
, et al.
·
Journal of Clinical Oncology
·
12
DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.
2018
·
Maud Toulmonde
, Isabelle Laure Ray-Coquard
, et al.
·
Journal of Clinical Oncology
·
11
Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy
2021
·
Amandine Crombé
, Lisa Gauquelin
, et al.
·
Diagnostic and Interventional Imaging
·
10
PDF
Abstract P1-18-04: Feasibility of palbociclib in women aged 70 and older with resistant and/or pretreated advanced breast cancer in the PALOMAGE study
2022
·
Etienne Brain
, Marina Pulido
, et al.
·
Cancer Research
·
8
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study
2024
·
Cheng-Ming Sun
, Maud Toulmonde
, et al.
·
Molecular Cancer
·
7
PDF
Le rôle des cohortes d’expansion dans les essais de phase I en cancérologie : des recommandations du HUB phase I
2015
·
Monia Ezzalfani
, Audrey Dugué
, et al.
·
Bulletin du Cancer
·
7
PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies.
2018
·
Maud Toulmonde
, Thomas Grellety
, et al.
·
Journal of Clinical Oncology
·
6
Abstract PS12-05: First efficacy results of a 2-stage Simon’s design randomised phase 2 of darolutamide or capecitabine in patients with triple-negative, androgen receptor positive advanced breast cancer (UCBG06-3)
2021
·
Hervé Bonnefoi
, Florence Lerebours
, et al.
·
Cancer Research
·
4
Show more works
View as search
Works count:
81
Citation count:
1,132
H-index:
15
I10-index:
20
Year
Topic
Type